{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:58:38Z","timestamp":1792112318933,"version":"4.4.0"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T00:00:00Z","timestamp":1668384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T00:00:00Z","timestamp":1668384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100016230","name":"Steven and Alexandra Cohen Foundation","doi-asserted-by":"publisher","award":["The Johns Hopkins Center for Psychedelic"],"award-info":[{"award-number":["The Johns Hopkins Center for Psychedelic"]}],"id":[{"id":"10.13039\/100016230","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016230","name":"Steven and Alexandra Cohen Foundation","doi-asserted-by":"publisher","award":["Consciousness Research"],"award-info":[{"award-number":["Consciousness Research"]}],"id":[{"id":"10.13039\/100016230","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016230","name":"Steven and Alexandra Cohen Foundation","doi-asserted-by":"publisher","award":["The Johns Hopkins Center for Psychedelic"],"award-info":[{"award-number":["The Johns Hopkins Center for Psychedelic"]}],"id":[{"id":"10.13039\/100016230","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016230","name":"Steven and Alexandra Cohen Foundation","doi-asserted-by":"publisher","award":["Consciousness Research"],"award-info":[{"award-number":["Consciousness Research"]}],"id":[{"id":"10.13039\/100016230","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Private philanthropic contributions from Tim Ferriss, Matt Mullenweg, Craig Nerenberg, and Blake Mycoskie","award":["The Johns Hopkins Center for Psychedelic"],"award-info":[{"award-number":["The Johns Hopkins Center for Psychedelic"]}]},{"name":"Private philanthropic contributions from Tim Ferriss, Matt Mullenweg, Craig Nerenberg, and Blake Mycoskie","award":["Consciousness Research"],"award-info":[{"award-number":["Consciousness Research"]}]},{"name":"Private philanthropic contributions from Tim Ferriss, Matt Mullenweg, Craig Nerenberg, and Blake Mycoskie","award":["The Johns Hopkins Center for Psychedelic"],"award-info":[{"award-number":["The Johns Hopkins Center for Psychedelic"]}]},{"name":"Private philanthropic contributions from Tim Ferriss, Matt Mullenweg, Craig Nerenberg, and Blake Mycoskie","award":["Consciousness Research"],"award-info":[{"award-number":["Consciousness Research"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Psychiatry Rep"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s11920-022-01394-5","type":"journal-article","created":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T03:08:48Z","timestamp":1668395328000},"page":"767-775","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Psychedelic-Assisted Therapy for People with Eating Disorders"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3567-1421","authenticated-orcid":false,"given":"Natalie","family":"Gukasyan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen C.","family":"Schreyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland R.","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela S.","family":"Guarda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,14]]},"reference":[{"key":"1394_CR1","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s00213-006-0457-5","volume":"187","author":"RR Griffiths","year":"2006","unstructured":"Griffiths RR, Richards WA, McCann U, Jesse R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology. 2006;187:268\u201383.","journal-title":"Psychopharmacology"},{"key":"1394_CR2","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1177\/0269881108094300","volume":"22","author":"RR Griffiths","year":"2008","unstructured":"Griffiths RR, Richards WA, Johnson MW, McCann UD, Jesse R. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol (Oxf). 2008;22:621\u201332.","journal-title":"J Psychopharmacol (Oxf)"},{"key":"1394_CR3","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2022.2096","author":"MP Bogenschutz","year":"2022","unstructured":"Bogenschutz MP, Ross S, Bhatt S, et al. Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial. JAMA Psychiat. 2022. https:\/\/doi.org\/10.1001\/jamapsychiatry.2022.2096.","journal-title":"JAMA Psychiat"},{"key":"1394_CR4","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","volume":"3","author":"RL Carhart-Harris","year":"2016","unstructured":"Carhart-Harris RL, Bolstridge M, Rucker J, Day CM, Erritzoe D, Kaelen M, Bloomfield M, Rickard JA, Forbes B, Feilding A. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry. 2016;3:619\u201327.","journal-title":"Lancet Psychiatry"},{"key":"1394_CR5","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1177\/0269881114548296","volume":"28","author":"MW Johnson","year":"2014","unstructured":"Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol (Oxf). 2014;28:983\u201392.","journal-title":"J Psychopharmacol (Oxf)"},{"key":"1394_CR6","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.4088\/JCP.v67n1110","volume":"67","author":"FA Moreno","year":"2006","unstructured":"Moreno FA, Wiegand CB, Taitano EK, Delgado PL. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry. 2006;67:1735.","journal-title":"J Clin Psychiatry"},{"key":"1394_CR7","doi-asserted-by":"crossref","unstructured":"Mitchell JM, Bogenschutz M, Lilienstein A, Harrison C, Kleiman S, Parker-Guilbert K, Ot\u2019alora G M, Garas W, Paleos C, Gorman I. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med. 2021;27:1025\u201333.","DOI":"10.1038\/s41591-021-01336-3"},{"key":"1394_CR8","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1002\/erv.2503","volume":"25","author":"AE Duncan","year":"2017","unstructured":"Duncan AE, Ziobrowski HN, Nicol G. The prevalence of past 12-month and lifetime DSM-IV eating disorders by BMI category in US men and women. Eur Eat Disord Rev. 2017;25:165\u201371.","journal-title":"Eur Eat Disord Rev"},{"key":"1394_CR9","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1097\/YCO.0000000000000276","volume":"29","author":"HE Erskine","year":"2016","unstructured":"Erskine HE, Whiteford HA, Pike KM. The global burden of eating disorders. Curr Opin Psychiatry. 2016;29:346\u201353.","journal-title":"Curr Opin Psychiatry"},{"key":"1394_CR10","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.psychres.2015.09.008","volume":"230","author":"S Ulfvebrand","year":"2015","unstructured":"Ulfvebrand S, Birgeg\u00e5rd A, Norring C, H\u00f6gdahl L, von Hausswolff-Juhlin Y. Psychiatric comorbidity in women and men with eating disorders results from a large clinical database. Psychiatry Res. 2015;230:294\u20139.","journal-title":"Psychiatry Res"},{"key":"1394_CR11","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1097\/YCO.0000000000000739","volume":"34","author":"AE Eeden","year":"2021","unstructured":"Eeden AE, Hoeken D, Hoek HW. Incidence, prevalence and mortality of anorexia nervosa and bulimia nervosa. Curr Opin Psychiatry. 2021;34:515\u201324.","journal-title":"Curr Opin Psychiatry"},{"key":"1394_CR12","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.physbeh.2007.11.020","volume":"94","author":"AS Guarda","year":"2008","unstructured":"Guarda AS. Treatment of anorexia nervosa: insights and obstacles. Physiol Behav. 2008;94:113\u201320.","journal-title":"Physiol Behav"},{"key":"1394_CR13","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1001\/jamapsychiatry.2021.3972","volume":"79","author":"J Phelps","year":"2022","unstructured":"Phelps J, Shah RN, Lieberman JA. The rapid rise in investment in psychedelics\u2014cart before the horse. JAMA Psychiat. 2022;79:189\u201390.","journal-title":"JAMA Psychiat"},{"key":"1394_CR14","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1001\/jama.2021.12481","volume":"326","author":"WR Smith","year":"2021","unstructured":"Smith WR, Appelbaum PS. Two models of legalization of psychedelic substances: reasons for concern. JAMA. 2021;326:697\u20138.","journal-title":"JAMA"},{"key":"1394_CR15","doi-asserted-by":"crossref","unstructured":"Flaherty GT, Maxemous KK, Nossier RE, Bui Y-G.\u00a0The highs and lows of drug tourism: a travel medicine perspective. J. Travel Med. 2017;24.","DOI":"10.1093\/jtm\/tax068"},{"key":"1394_CR16","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.neulet.2011.01.046","volume":"493","author":"JL Moreno","year":"2011","unstructured":"Moreno JL, Holloway T, Albizu L, Sealfon SC, Gonz\u00e1lez-Maeso J. Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists. Neurosci Lett. 2011;493:76\u20139.","journal-title":"Neurosci Lett"},{"key":"1394_CR17","doi-asserted-by":"crossref","unstructured":"Nichols DE.\u00a0Psychedelics. 2016;264\u2013355.","DOI":"10.1124\/pr.115.011478"},{"key":"1394_CR18","doi-asserted-by":"crossref","unstructured":"Nau F Jr, Yu B, Martin D, Nichols CD. Serotonin 5-HT2A receptor activation blocks TNF-\u03b1 mediated inflammation in vivo. PLoS One. 2013;8:e75426.","DOI":"10.1371\/journal.pone.0075426"},{"key":"1394_CR19","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.1016\/j.celrep.2018.05.022","volume":"23","author":"C Ly","year":"2018","unstructured":"Ly C, Greb AC, Cameron LP, Wong JM, Barragan EV, Wilson PC, Burbach KF, Zarandi SS, Sood A, Paddy MR. Psychedelics promote structural and functional neural plasticity. Cell Rep. 2018;23:3170\u201382.","journal-title":"Cell Rep"},{"key":"1394_CR20","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1097\/00007691-200404000-00009","volume":"26","author":"R De la Torre","year":"2004","unstructured":"De la Torre R, Farr\u00e9 M, Roset PN, Pizarro N, Abanades S, Segura M, Segura J, Cam\u00ed J. Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther Drug Monit. 2004;26:137\u201344.","journal-title":"Ther Drug Monit"},{"key":"1394_CR21","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1093\/ijnp\/pyaa087","volume":"24","author":"B Kadriu","year":"2021","unstructured":"Kadriu B, Greenwald M, Henter ID, Gilbert JR, Kraus C, Park LT, Zarate CA. Ketamine and serotonergic psychedelics: common mechanisms underlying the effects of rapid-acting antidepressants. Int J Neuropsychopharmacol. 2021;24:8\u201321.","journal-title":"Int J Neuropsychopharmacol"},{"key":"1394_CR22","doi-asserted-by":"publisher","first-page":"382","DOI":"10.3390\/brainsci12030382","volume":"12","author":"A Ragnhildstveit","year":"2022","unstructured":"Ragnhildstveit A, Slayton M, Jackson LK, Brendle M, Ahuja S, Holle W, Moore C, Sollars K, Seli P, Robison R. Ketamine as a novel psychopharmacotherapy for eating disorders: evidence and future directions. Brain Sci. 2022;12:382.","journal-title":"Brain Sci"},{"key":"1394_CR23","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1177\/0269881108093587","volume":"22","author":"MW Johnson","year":"2008","unstructured":"Johnson MW, Richards WA, Griffiths RR. Human hallucinogen research: guidelines for safety. J Psychopharmacol (Oxf). 2008;22:603\u201320.","journal-title":"J Psychopharmacol (Oxf)"},{"key":"1394_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2018.05.012","author":"MW Johnson","year":"2018","unstructured":"Johnson MW, Griffiths RR, Hendricks PS, Henningfield JE. The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. Neuropharmacology. 2018. https:\/\/doi.org\/10.1016\/j.neuropharm.2018.05.012.","journal-title":"Neuropharmacology"},{"key":"1394_CR25","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.pharmthera.2003.11.002","volume":"101","author":"DE Nichols","year":"2004","unstructured":"Nichols DE. Hallucinogens. Pharmacol Ther. 2004;101:131\u201381.","journal-title":"Pharmacol Ther"},{"key":"1394_CR26","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00213-017-4771-x","volume":"235","author":"RL Carhart-Harris","year":"2018","unstructured":"Carhart-Harris RL, Bolstridge M, Day CMJ, Rucker J, Watts R, Erritzoe DE, Kaelen M, Giribaldi B, Bloomfield M, Pilling S. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology. 2018;235:399\u2013408.","journal-title":"Psychopharmacology"},{"key":"1394_CR27","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/0269881116675513","volume":"30","author":"RR Griffiths","year":"2016","unstructured":"Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, Cosimano MP, Klinedinst MA. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol Oxf Engl. 2016;30:1181\u201397.","journal-title":"J Psychopharmacol Oxf Engl"},{"key":"1394_CR28","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1177\/0269881116662634","volume":"30","author":"TM Carbonaro","year":"2016","unstructured":"Carbonaro TM, Bradstreet MP, Barrett FS, MacLean KA, Jesse R, Johnson MW, Griffiths RR. Survey study of challenging experiences after ingesting psilocybin mushrooms: acute and enduring positive and negative consequences. J Psychopharmacol (Oxf). 2016;30:1268\u201378.","journal-title":"J Psychopharmacol (Oxf)"},{"key":"1394_CR29","unstructured":"Hofmann A.\u00a0LSD, my problem child: reflections on sacred drugs, mysticism, and Sci. 1983;209."},{"key":"1394_CR30","unstructured":"Grinspoon L, Bakalar JB.\u00a0Psychedelic drugs reconsidered. Basic Books New York. 1979."},{"key":"1394_CR31","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1177\/0269881116679368","volume":"30","author":"JJH Rucker","year":"2016","unstructured":"Rucker JJH, Jelen LA, Flynn S, Frowde KD, Young AH. Psychedelics in the treatment of unipolar mood disorders: a systematic review. J Psychopharmacol (Oxf). 2016;30:1220\u20139.","journal-title":"J Psychopharmacol (Oxf)"},{"key":"1394_CR32","doi-asserted-by":"publisher","first-page":"205032451668332","DOI":"10.1177\/2050324516683325","volume":"3","author":"I Hartogsohn","year":"2017","unstructured":"Hartogsohn I. Constructing drug effects: a history of set and setting. Drug Sci Policy Law. 2017;3:205032451668332.","journal-title":"Drug Sci Policy Law"},{"key":"1394_CR33","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","volume":"78","author":"AK Davis","year":"2021","unstructured":"Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW, Finan PH, Griffiths RR. Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiat. 2021;78:481\u20139.","journal-title":"JAMA Psychiat"},{"key":"1394_CR34","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1177\/02698811211073759","volume":"36","author":"N Gukasyan","year":"2022","unstructured":"Gukasyan N, Davis AK, Barrett FS, Cosimano MP, Sepeda ND, Johnson MW, Griffiths RR. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: prospective 12-month follow-up. J Psychopharmacol (Oxf). 2022;36:151\u20138.","journal-title":"J Psychopharmacol (Oxf)"},{"key":"1394_CR35","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1177\/0269881116675512","volume":"30","author":"S Ross","year":"2016","unstructured":"Ross S, Bossis A, Guss J, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol (Oxf). 2016;30:1165\u201380.","journal-title":"J Psychopharmacol (Oxf)"},{"key":"1394_CR36","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1176\/appi.ajp.2012.12081074","volume":"170","author":"BT Walsh","year":"2013","unstructured":"Walsh BT. The enigmatic persistence of anorexia nervosa. Am J Psychiatry. 2013;170:477\u201384.","journal-title":"Am J Psychiatry"},{"key":"1394_CR37","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.cpr.2005.04.012","volume":"25","author":"SE Cassin","year":"2005","unstructured":"Cassin SE, Ranson KM. Personality and eating disorders: a decade in review. Clin Psychol Rev. 2005;25:895\u2013916.","journal-title":"Clin Psychol Rev"},{"key":"1394_CR38","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1521\/pedi.2006.20.4.401","volume":"20","author":"L Claes","year":"2006","unstructured":"Claes L, Vandereycken W, Luyten P, Soenens B, Pieters G, Vertommen H. Personality prototypes in eating disorders based on the big five model. J Personal Disord Cassin Von Ranson. 2006;20:401\u201316.","journal-title":"J Personal Disord Cassin Von Ranson"},{"key":"1394_CR39","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.comppsych.2008.07.010","volume":"50","author":"S Fassino","year":"2009","unstructured":"Fassino S, Amianto F, Abbate-Daga G. The dynamic relationship of parental personality traits with the personality and psychopathology traits of anorectic and bulimic daughters. Compr Psychiatry. 2009;50:232\u20139.","journal-title":"Compr Psychiatry"},{"key":"1394_CR40","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.cpr.2005.10.003","volume":"26","author":"LR Lilenfeld","year":"2006","unstructured":"Lilenfeld LR, Wonderlich S, Riso LP, Crosby R, Mitchell J. Eating disorders and personality: a methodological and empirical review. Clin Psychol Rev. 2006;26:299\u2013320.","journal-title":"Clin Psychol Rev"},{"key":"1394_CR41","doi-asserted-by":"crossref","unstructured":"Dufresne L, Bussi\u00e8res E-L, B\u00e9dard A, Gingras N, Blanchette-Sarrasin A, B\u00e9gin PhD C. Personality traits in adolescents with eating disorder: a meta-analytic review. Int J Eat Disord. 2020;53:157\u201373.","DOI":"10.1002\/eat.23183"},{"key":"1394_CR42","first-page":"131","volume":"5","author":"Z Yilmaz","year":"2015","unstructured":"Yilmaz Z, Hardaway JA, Bulik CM. Genetics and epigenetics of eating disorders. Adv Genomics Genet. 2015;5:131.","journal-title":"Adv Genomics Genet"},{"key":"1394_CR43","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.psc.2018.10.007","volume":"42","author":"CM Bulik","year":"2019","unstructured":"Bulik CM, Blake L, Austin J. Genetics of eating disorders: what the clinician needs to know. Psychiatr Clin North Am. 2019;42:59\u201373.","journal-title":"Psychiatr Clin North Am"},{"key":"1394_CR44","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1038\/s41588-019-0439-2","volume":"51","author":"HJ Watson","year":"2019","unstructured":"Watson HJ, Yilmaz Z, Thornton LM, Hubel C, Coleman JRI, Gaspar HA, Bulik CM. Genome-wide association study identifies eight risk loci and implicates metabo-psychiatric origins for anorexia nervosa. Nat Genet. 2019;51:1207\u201314.","journal-title":"Nat Genet"},{"key":"1394_CR45","unstructured":"National Institute for Health and Care Excellence.\u00a0Eating disorders: recognition and treatment. 2017."},{"key":"1394_CR46","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1002\/eat.23376","volume":"53","author":"J Sansfacon","year":"2020","unstructured":"Sansfacon J, Booij L, Gauvin L, Fletcher E, Islam F, Israel M, Steiger H. Pretreatment motivation and therapy outcomes in eating disorders: a systematic review and meta-analysis. Int J Eat Disord. 2020;53:1879\u2013900.","journal-title":"Int J Eat Disord"},{"key":"1394_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-244X-9-67","volume":"9","author":"S Fassino","year":"2009","unstructured":"Fassino S, Pier\u00f2 A, Tomba E, Abbate-Daga G. Factors associated with dropout from treatment for eating disorders: a comprehensive literature review. BMC Psychiatry. 2009;9:1\u20139.","journal-title":"BMC Psychiatry"},{"key":"1394_CR48","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1097\/YCO.0000000000000453","volume":"31","author":"T Berends","year":"2018","unstructured":"Berends T, Boonstra N, Van Elburg A. Relapse in anorexia nervosa: a systematic review and meta-analysis. Curr Opin Psychiatry. 2018;31:445\u201355.","journal-title":"Curr Opin Psychiatry"},{"key":"1394_CR49","doi-asserted-by":"publisher","first-page":"836","DOI":"10.3390\/jpm12050836","volume":"12","author":"S Frostad","year":"2022","unstructured":"Frostad S, Rozakou-Soumalia N, D\u00e2rvariu \u015e, Foruzesh B, Azkia H, Larsen MP, Rowshandel E, Sj\u00f6gren JM. BMI at discharge from treatment predicts relapse in anorexia nervosa: a systematic scoping review. J Pers Med. 2022;12:836.","journal-title":"J Pers Med"},{"key":"1394_CR50","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1124\/jpet.300.2.468","volume":"300","author":"NR Hanley","year":"2002","unstructured":"Hanley NR, Hensler JG. Mechanisms of ligand-induced desensitization of the 5-hydroxytryptamine(2A) receptor. J Pharmacol Exp Ther. 2002;300:468.","journal-title":"J Pharmacol Exp Ther"},{"key":"1394_CR51","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/bs.pmbts.2015.02.009","volume":"132","author":"M Darmon","year":"2015","unstructured":"Darmon M, Awabdh SA, Emerit MB, Masson J. Insights into serotonin receptor trafficking: cell membrane targeting and internalization. Prog Mol Biol Transl Sci. 2015;132:97.","journal-title":"Prog Mol Biol Transl Sci"},{"key":"1394_CR52","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1097\/00004714-199812000-00005","volume":"18","author":"N Bonhomme","year":"1998","unstructured":"Bonhomme N. Involvement of serotonin and dopamine in the mechanism of action of novel antidepressant drugs: a review. J Clin Psychopharmacol. 1998;18:447.","journal-title":"J Clin Psychopharmacol"},{"key":"1394_CR53","unstructured":"De Vry J, Schreiber R.\u00a0Effects of selected serotonin 5-HT 1 and 5-HT 2 receptor agonists on feeding behavior: possible mechanisms of action. 2017."},{"key":"1394_CR54","doi-asserted-by":"crossref","unstructured":"Stockmeier CA.\u00a0Neurobiology of serotonin in depression and suicide. Neurobiol Suicide Bench Clin. 1997;220.","DOI":"10.1111\/j.1749-6632.1997.tb52362.x"},{"key":"1394_CR55","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/0006-3223(88)90113-8","volume":"23","author":"WH Kaye","year":"1988","unstructured":"Kaye WH, Gwirtsman HE, George DT, Jimerson DC, Ebert MH. CSF 5-HIAA concentrations in anorexia nervosa: reduced values in underweight subjects normalize after weight gain. Biol Psychiatry. 1988;23:102\u20135.","journal-title":"Biol Psychiatry"},{"key":"1394_CR56","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/S0006-3223(02)01378-1","volume":"52","author":"GK Frank","year":"2002","unstructured":"Frank GK, Kaye WH, Meltzer CC, Price JC, Greer P, McConaha C, Skovira K. Reduced 5-HT2A receptor binding after recovery from anorexia nervosa. Biol Psychiatry. 2002;52:896\u2013906.","journal-title":"Biol Psychiatry"},{"key":"1394_CR57","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S0014-2999(00)00812-8","volume":"410","author":"A Hinney","year":"2000","unstructured":"Hinney A, Remschmidt H, Hebebrand J. Candidate gene polymorphisms in eating disorders. Eur J Pharmacol. 2000;410:147.","journal-title":"Eur J Pharmacol"},{"key":"1394_CR58","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s00702-011-0699-1","volume":"119","author":"S Walitza","year":"2012","unstructured":"Walitza S, Bov DS, Romanos M, et al. Pilot study on HTR2A promoter polymorphism,-1438G\/A (rs6311) and a nearby copy number variation showed association with onset and severity in early onset obsessivecompulsive disorder. J Neural Transm. 2012;119:507.","journal-title":"J Neural Transm"},{"key":"1394_CR59","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1073\/pnas.1119598109","volume":"109","author":"RL Carhart-Harris","year":"2012","unstructured":"Carhart-Harris RL, Erritzoe D, Williams T, et al. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci. 2012;109:2138\u201343.","journal-title":"Proc Natl Acad Sci"},{"key":"1394_CR60","doi-asserted-by":"publisher","DOI":"10.3389\/fnhum.2014.00020","author":"RL Carhart-Harris","year":"2014","unstructured":"Carhart-Harris RL, Leech R, Hellyer PJ, Shanahan M, Feilding A, Tagliazucchi E, Chialvo DR, Nutt D. The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs. Front Hum Neurosci. 2014. https:\/\/doi.org\/10.3389\/fnhum.2014.00020.","journal-title":"Front Hum Neurosci"},{"key":"1394_CR61","doi-asserted-by":"crossref","unstructured":"Palhano-Fontes F, Andrade KC, Tofoli LF, Santos AC, Crippa JAS, Hallak JEC, Ribeiro S, de Araujo DB. The psychedelic state induced by ayahuasca modulates the activity and connectivity of the default mode network. PLoS One. 2015;10:e0118143.","DOI":"10.1371\/journal.pone.0118143"},{"key":"1394_CR62","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.pscychresns.2013.11.004","volume":"221","author":"S Lee","year":"2014","unstructured":"Lee S, Kim KR, Ku J, Lee J-H, Namkoong K, Jung Y-C. Resting-state synchrony between anterior cingulate cortex and precuneus relates to body shape concern in anorexia nervosa and bulimia nervosa. Psychiatry Res Neuroimaging. 2014;221:43.","journal-title":"Psychiatry Res Neuroimaging"},{"key":"1394_CR63","doi-asserted-by":"publisher","first-page":"346","DOI":"10.3389\/fnbeh.2014.00346","volume":"8","author":"I Boehm","year":"2014","unstructured":"Boehm I, Geisler D, King JA, et al. Increased resting state functional connectivity in the fronto-parietal and default mode network in anorexia nervosa. Front Behav Neurosci. 2014;8:346.","journal-title":"Front Behav Neurosci"},{"key":"1394_CR64","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1503\/jpn.150259","volume":"41","author":"I Boehm","year":"2016","unstructured":"Boehm I, Geisler D, Tam F, et al. Partially restored resting-state functional connectivity in women recovered from anorexia nervosa. J Psychiatry Neurosci. 2016;41:377.","journal-title":"J Psychiatry Neurosci"},{"key":"1394_CR65","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.biopsych.2014.04.010","volume":"78","author":"R Kraehenmann","year":"2015","unstructured":"Kraehenmann R, Preller KH, Scheidegger M, Pokorny T, Bosch OG, Seifritz E, Vollenweider FX. Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers. Biol Psychiatry. 2015;78:572\u201381.","journal-title":"Biol Psychiatry"},{"key":"1394_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-59282-y","volume":"10","author":"FS Barrett","year":"2020","unstructured":"Barrett FS, Doss MK, Sepeda ND, Pekar JJ, Griffiths RR. Emotions and brain function are altered up to one month after a single high dose of psilocybin. Sci Rep. 2020;10:1\u201314.","journal-title":"Sci Rep"},{"key":"1394_CR67","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/erv.2197","volume":"20","author":"Y Zhu","year":"2012","unstructured":"Zhu Y, Hu X, Wang J, Chen J, Guo Q, Li C, Enck P. Processing of food, body and emotional stimuli in anorexia nervosa: a systematic review and meta-analysis of functional magnetic resonance imaging studies. Eur Eat Disord Rev. 2012;20:439\u201350.","journal-title":"Eur Eat Disord Rev"},{"key":"1394_CR68","doi-asserted-by":"publisher","first-page":"444","DOI":"10.3109\/15622975.2011.562244","volume":"12","author":"MK Brandys","year":"2011","unstructured":"Brandys MK, Kas MJ, Van Elburg AA, Campbell IC, Adan RA. A meta-analysis of circulating BDNF concentrations in anorexia nervosa. World J Biol Psychiatry. 2011;12:444\u201354.","journal-title":"World J Biol Psychiatry"},{"key":"1394_CR69","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.psyneuen.2014.09.031","volume":"51","author":"M Solmi","year":"2015","unstructured":"Solmi M, Veronese N, Favaro A, Santonastaso P, Manzato E, Sergi G, Correll CU. Inflammatory cytokines and anorexia nervosa: a meta-analysis of cross-sectional and longitudinal studies. Psychoneuroendocrinology. 2015;51:237\u201352.","journal-title":"Psychoneuroendocrinology"},{"key":"1394_CR70","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jcbs.2019.11.004","volume":"15","author":"AK Davis","year":"2020","unstructured":"Davis AK, Barrett FS, Griffiths RR. Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety. J Context Behav Sci. 2020;15:39\u201345.","journal-title":"J Context Behav Sci"},{"key":"1394_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41398-021-01706-y","volume":"11","author":"MK Doss","year":"2021","unstructured":"Doss MK, Pova\u017ean M, Rosenberg MD, Sepeda ND, Davis AK, Finan PH, Smith GS, Pekar JJ, Barker PB, Griffiths RR. Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder. Transl Psychiatry. 2021;11:1\u201310.","journal-title":"Transl Psychiatry"},{"key":"1394_CR72","unstructured":"Milton LK, Farrell GA, Oldfield BJ, Foldi CJ.\u00a0Effects of psilocybin on activity-based anorexia and cognitive flexibility in female rats. 2022."},{"key":"1394_CR73","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1177\/0269881111420188","volume":"25","author":"KA MacLean","year":"2011","unstructured":"MacLean KA, Johnson MW, Griffiths RR. Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. J Psychopharmacol (Oxf). 2011;25:1453\u201361.","journal-title":"J Psychopharmacol (Oxf)"},{"key":"1394_CR74","doi-asserted-by":"publisher","first-page":"974","DOI":"10.3389\/fphar.2017.00974","volume":"8","author":"L Roseman","year":"2018","unstructured":"Roseman L, Nutt DJ, Carhart-Harris RL. Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Front Pharmacol. 2018;8:974.","journal-title":"Front Pharmacol"},{"key":"1394_CR75","doi-asserted-by":"crossref","unstructured":"Garcia-Romeu A, Davis AK, Erowid F, Erowid E, Griffiths RR, Johnson MW.\u00a0Cessation and reduction in alcohol consumption and misuse after psychedelic use. J Psychopharmacol (Oxf) 2019;0269881119845793.","DOI":"10.1177\/0269881119845793"},{"key":"1394_CR76","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.jad.2020.09.003","volume":"277","author":"L Mandelli","year":"2020","unstructured":"Mandelli L, Draghetti S, Albert U, De Ronchi D, Atti A-R. Rates of comorbid obsessive-compulsive disorder in eating disorders: a meta-analysis of the literature. J Affect Disord. 2020;277:927\u201339.","journal-title":"J Affect Disord"},{"key":"1394_CR77","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s40519-016-0357-6","volume":"22","author":"LK Fewell","year":"2017","unstructured":"Fewell LK, Levinson CA, Stark L. Depression, worry, and psychosocial functioning predict eating disorder treatment outcomes in a residential and partial hospitalization setting. Eat Weight Disord - Stud Anorex Bulim Obes. 2017;22:291\u2013301.","journal-title":"Eat Weight Disord - Stud Anorex Bulim Obes"},{"key":"1394_CR78","unstructured":"Delay J, Pichot P, Lemp\u00e9ri\u00e8re T, Quetin A.\u00a0Effets th\u00e9rapeutiques de la psilocybine sur une n\u00e9vrose convulsive. Ann. M\u00e9d.-Psychol. 1959."},{"key":"1394_CR79","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/j.1600-0447.1964.tb04950.x","volume":"39","author":"G Johnsen","year":"1964","unstructured":"Johnsen G. Three years experience with the use of LSD as an aid in psychotherapy. Acta Psychiatr Scand. 1964;39:383\u20138.","journal-title":"Acta Psychiatr Scand"},{"key":"1394_CR80","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1177\/0957154X16629902","volume":"27","author":"JK Larsen","year":"2016","unstructured":"Larsen JK. Neurotoxicity and LSD treatment: a follow-up study of 151 patients in Denmark. Hist Psychiatry. 2016;27:172\u201389.","journal-title":"Hist Psychiatry"},{"key":"1394_CR81","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1080\/02791072.2017.1361559","volume":"49","author":"A Lafrance","year":"2017","unstructured":"Lafrance A, Loizaga-Velder A, Fletcher J, Renelli M, Files N, Tupper KW. Nourishing the spirit: exploratory research on ayahuasca experiences along the continuum of recovery from eating disorders. J Psychoactive Drugs. 2017;49:427\u201335.","journal-title":"J Psychoactive Drugs"},{"key":"1394_CR82","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1007\/s40519-020-01000-8","volume":"26","author":"MJ Spriggs","year":"2021","unstructured":"Spriggs MJ, Kettner H, Carhart-Harris RL. Positive effects of psychedelics on depression and wellbeing scores in individuals reporting an eating disorder. Eat Weight Disord-Stud Anorex Bulim Obes. 2021;26:1265\u201370.","journal-title":"Eat Weight Disord-Stud Anorex Bulim Obes"},{"key":"1394_CR83","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jpsychires.2022.03.008","volume":"149","author":"TD Brewerton","year":"2022","unstructured":"Brewerton TD, Wang JB, Lafrance A, Pamplin C, Mithoefer M, Yazar-Klosinki B, Emerson A, Doblin R. MDMA-assisted therapy significantly reduces eating disorder symptoms in a randomized placebo-controlled trial of adults with severe PTSD. J Psychiatr Res. 2022;149:128\u201335.","journal-title":"J Psychiatr Res"},{"key":"1394_CR84","unstructured":"Knatz Peck S, Kaye W. Safety, acceptability, and preliminary efficacy of a 25 mg dose of psilocybin with psychological support for Anorexia Nervosa. Presented at Academy for Eating Disorders 2022 Annual Meeting (virtual)."},{"key":"1394_CR85","doi-asserted-by":"publisher","unstructured":"Gukasyan N, Nayak SM. Psychedelics, placebo effects, and set and setting: Insights from common factors theory of psychotherapy. Transcult Psychiatry. 2022;56(5):652\u2013664. https:\/\/doi.org\/10.1177\/1363461520983684","DOI":"10.1177\/1363461520983684"},{"key":"1394_CR86","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1177\/0269881116677852","volume":"30","author":"I Hartogsohn","year":"2016","unstructured":"Hartogsohn I. Set and setting, psychedelics and the placebo response: an extra-pharmacological perspective on psychopharmacology. J Psychopharmacol (Oxf). 2016;30:1259\u201367.","journal-title":"J Psychopharmacol (Oxf)"},{"key":"1394_CR87","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1080\/17512433.2021.1933434","volume":"14","author":"SD Muthukumaraswamy","year":"2021","unstructured":"Muthukumaraswamy SD, Forsyth A, Lumley T. Blinding and expectancy confounds in psychedelic randomized controlled trials. Expert Rev Clin Pharmacol. 2021;14:1133\u201352.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"1394_CR88","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1007\/s00213-018-4981-x","volume":"235","author":"FS Barrett","year":"2018","unstructured":"Barrett FS, Carbonaro TM, Hurwitz E, Johnson MW, Griffiths RR. Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: effects on cognition. Psychopharmacology. 2018;235:2915\u201327.","journal-title":"Psychopharmacology"},{"key":"1394_CR89","doi-asserted-by":"crossref","unstructured":"Bonson KR, Buckholtz JW, Murphy DL. Chronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans.\u00a0Neuropsychopharmacol Rep. 1996;14(6):425-36.","DOI":"10.1016\/0893-133X(95)00145-4"},{"key":"1394_CR90","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s00213-006-0576-z","volume":"189","author":"M Tancer","year":"2007","unstructured":"Tancer M, Johanson C-E. The effects of fluoxetine on the subjective and physiological effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology. 2007;189:565\u201373.","journal-title":"Psychopharmacology"},{"key":"1394_CR91","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1056\/NEJMc2108082","volume":"385","author":"RL Carhart-Harris","year":"2021","unstructured":"Carhart-Harris RL, Blemings A, Nutt DJ. Psilocybin for depression. N Engl J Med. 2021;385:862\u20134.","journal-title":"N Engl J Med"},{"key":"1394_CR92","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-020-05710-w","author":"AA Feduccia","year":"2020","unstructured":"Feduccia AA, Jerome L, Mithoefer MC, Holland J. Discontinuation of medications classified as reuptake inhibitors affects treatment response of MDMA-assisted psychotherapy. Psychopharmacology. 2020. https:\/\/doi.org\/10.1007\/s00213-020-05710-w.","journal-title":"Psychopharmacology"},{"key":"1394_CR93","doi-asserted-by":"crossref","unstructured":"Yaden DB, Potash JB, Griffiths RR.\u00a0Preparing for the bursting of the psychedelic hype bubble. JAMA Psychiatry. 2022.","DOI":"10.1001\/jamapsychiatry.2022.2546"},{"key":"1394_CR94","unstructured":"COMPASS Pathways Press Release.\u00a0COMPASS pathways launches phase II clinical trial of psilocybin therapy in anorexia nervosa. 2022. https:\/\/compasspathways.com\/compass-pathways-launches-phase-ii-clinical-trial-of-psilocybin-therapy-in-anorexia-nervosa\/. Accessed 8 Sep 2022."}],"container-title":["Current Psychiatry Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11920-022-01394-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11920-022-01394-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11920-022-01394-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T04:17:32Z","timestamp":1671682652000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11920-022-01394-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,14]]},"references-count":94,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1394"],"URL":"https:\/\/doi.org\/10.1007\/s11920-022-01394-5","relation":{},"ISSN":["1523-3812","1535-1645"],"issn-type":[{"value":"1523-3812","type":"print"},{"value":"1535-1645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,14]]},"assertion":[{"value":"29 October 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Natalie Gukasyan: All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.): The Steven and Alexandra Cohen Foundation, Tim Ferriss, Matt Mullenweg, Craig Nerenberg, and Blake Mycoskie. Grants or contracts from any entity: Usona Institute. Payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing or educational events: Psychedemia Conference and NYU Psychedelic Medicine CME event. Support for attending meetings and\/or travel: Horizons 2022. Colleen C. Schreyer: All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.): Grant Funding: The Johns Hopkins Center for Psychedelic & Consciousness Research, 5% FTE. Roland R. Griffiths: All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.): Support from the Johns Hopkins Center for Psychedelic and Consciousness Research. Grants or contracts from any entity: PI on Usona psilocybin depression study; PI on NIDA grant focused on caffeine research; PI on sponsored and grant support for the Johns Hopkins Center for Psychedelic and Consciousness Research with funding provided by Tim Ferriss, Matt Mullenweg, Craig Nerenberg, Blake Mycoskie, and the Steven and Alexandra Cohen Foundation; and PI on psychedelic research sponsored by the Riverstyx Foundation, the Heffter Research Institute, the Turnbull family foundation, the Council on Spiritual Practices, and the Y.C. Ho\/Helen and Michael Chiang Foundation. Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Honoraria for presentations from University of California San Diego, Yale University, Manatt Phelps and Phillips, University of Rochester, Harvard University, Institute for Functional Medicine, Sheppard Pratt Health System, Innovations Consulting Group, Centre for Addiction and Mental Health. Support for attending meetings and\/or travel: Heffter Research Institute Board meeting. Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid: Director Johns Hopkins Center for Psychedelic and Consciousness Research and Member of Board of Directors of Heffter Research Foundation. Angela S. Guarda: All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.): Grant Funding: The Johns Hopkins Center for Psychedelic & Consciousness Research, 5% FTE.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}